Does the media favor ADMA or PBYI?

In the previous week, Puma Biotechnology had 4 more articles in the media than ADMA Biologics. MarketBeat recorded 6 mentions for Puma Biotechnology and 2 mentions for ADMA Biologics. ADMA Biologics' average media sentiment score of 1.51 beat Puma Biotechnology's score of 0.34 indicating that ADMA Biologics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ADMA Biologics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Puma Biotechnology 1 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to PBYI or CTMX?

In the previous week, Puma Biotechnology had 4 more articles in the media than CytomX Therapeutics. MarketBeat recorded 6 mentions for Puma Biotechnology and 2 mentions for CytomX Therapeutics. CytomX Therapeutics' average media sentiment score of 0.62 beat Puma Biotechnology's score of 0.34 indicating that CytomX Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Puma Biotechnology 1 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CytomX Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to TRDA or PBYI?

In the previous week, Puma Biotechnology had 5 more articles in the media than Entrada Therapeutics. MarketBeat recorded 6 mentions for Puma Biotechnology and 1 mentions for Entrada Therapeutics. Entrada Therapeutics' average media sentiment score of 1.34 beat Puma Biotechnology's score of 0.34 indicating that Entrada Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Entrada Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Puma Biotechnology 1 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation & earnings, PBYI or MESO?

Puma Biotechnology has higher revenue and earnings than Mesoblast. Mesoblast is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Puma Biotechnology $228.40M 2.10 $31.11M $0.52 17.85 Mesoblast $120.25M 16.51 -$57.50M -$0.28 N/A

Does the media prefer PBYI or MESO?

In the previous week, Puma Biotechnology had 4 more articles in the media than Mesoblast. MarketBeat recorded 6 mentions for Puma Biotechnology and 2 mentions for Mesoblast. Mesoblast's average media sentiment score of 0.83 beat Puma Biotechnology's score of 0.34 indicating that Mesoblast is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Puma Biotechnology 1 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Mesoblast 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer PBYI or COAG?

In the previous week, Puma Biotechnology had 1 more articles in the media than Hemab Therapeutics. MarketBeat recorded 6 mentions for Puma Biotechnology and 5 mentions for Hemab Therapeutics. Puma Biotechnology's average media sentiment score of 0.34 beat Hemab Therapeutics' score of 0.25 indicating that Puma Biotechnology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Puma Biotechnology 1 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Hemab Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Puma Biotechnology (PBYI) Competitors

$9.28 -0.54 (-5.50%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$9.29 +0.01 (+0.11%)

As of 09/23/2026 07:30 PM Eastern

Compare

PBYI vs. ADMA, CTMX, TRDA, MESO, and COAG

Should you buy Puma Biotechnology stock or one of its competitors? Puma Biotechnology's main competitors and comparable companies include ADMA Biologics (ADMA), CytomX Therapeutics (CTMX), Entrada Therapeutics (TRDA), Mesoblast (MESO), and Hemab Therapeutics (COAG). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Puma Biotechnology compare to ADMA Biologics?

ADMA Biologics (NASDAQ:ADMA) and Puma Biotechnology (NASDAQ:PBYI) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, earnings, valuation, profitability and institutional ownership.

75.7% of ADMA Biologics shares are held by institutional investors. Comparatively, 61.3% of Puma Biotechnology shares are held by institutional investors. 3.9% of ADMA Biologics shares are held by insiders. Comparatively, 22.2% of Puma Biotechnology shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

ADMA Biologics has higher revenue and earnings than Puma Biotechnology. ADMA Biologics is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADMA Biologics	$510.17M	4.26	$146.93M	$0.70	13.86
Puma Biotechnology	$228.40M	2.10	$31.11M	$0.52	17.85

ADMA Biologics has a net margin of 32.98% compared to Puma Biotechnology's net margin of 11.50%. ADMA Biologics' return on equity of 40.17% beat Puma Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ADMA Biologics	32.98%	40.17%	26.97%
Puma Biotechnology	11.50%	20.76%	13.22%

ADMA Biologics presently has a consensus target price of $18.67, indicating a potential upside of 92.44%. Puma Biotechnology has a consensus target price of $6.00, indicating a potential downside of 35.34%. Given ADMA Biologics' stronger consensus rating and higher possible upside, analysts plainly believe ADMA Biologics is more favorable than Puma Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADMA Biologics	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Puma Biotechnology	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

ADMA Biologics has a beta of 0.78, meaning that its stock price is 22% less volatile than the broader market. Comparatively, Puma Biotechnology has a beta of 1.24, meaning that its stock price is 24% more volatile than the broader market.

In the previous week, Puma Biotechnology had 4 more articles in the media than ADMA Biologics. MarketBeat recorded 6 mentions for Puma Biotechnology and 2 mentions for ADMA Biologics. ADMA Biologics' average media sentiment score of 1.51 beat Puma Biotechnology's score of 0.34 indicating that ADMA Biologics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ADMA Biologics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Puma Biotechnology	1 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

ADMA Biologics beats Puma Biotechnology on 12 of the 16 factors compared between the two stocks.

How does Puma Biotechnology compare to CytomX Therapeutics?

Puma Biotechnology (NASDAQ:PBYI) and CytomX Therapeutics (NASDAQ:CTMX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk, media sentiment and profitability.

61.3% of Puma Biotechnology shares are held by institutional investors. Comparatively, 67.8% of CytomX Therapeutics shares are held by institutional investors. 22.2% of Puma Biotechnology shares are held by insiders. Comparatively, 3.8% of CytomX Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Puma Biotechnology currently has a consensus price target of $6.00, suggesting a potential downside of 35.34%. CytomX Therapeutics has a consensus price target of $11.90, suggesting a potential upside of 328.06%. Given CytomX Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe CytomX Therapeutics is more favorable than Puma Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Puma Biotechnology	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
CytomX Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83

Puma Biotechnology has a net margin of 11.50% compared to CytomX Therapeutics' net margin of -435.21%. Puma Biotechnology's return on equity of 20.76% beat CytomX Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Puma Biotechnology	11.50%	20.76%	13.22%
CytomX Therapeutics	-435.21%	-38.46%	-30.33%

Puma Biotechnology has higher revenue and earnings than CytomX Therapeutics. CytomX Therapeutics is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Puma Biotechnology	$228.40M	2.10	$31.11M	$0.52	17.85
CytomX Therapeutics	$76.20M	7.95	-$17.37M	-$0.50	N/A

Puma Biotechnology has a beta of 1.24, meaning that its share price is 24% more volatile than the broader market. Comparatively, CytomX Therapeutics has a beta of 2.14, meaning that its share price is 114% more volatile than the broader market.

In the previous week, Puma Biotechnology had 4 more articles in the media than CytomX Therapeutics. MarketBeat recorded 6 mentions for Puma Biotechnology and 2 mentions for CytomX Therapeutics. CytomX Therapeutics' average media sentiment score of 0.62 beat Puma Biotechnology's score of 0.34 indicating that CytomX Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Puma Biotechnology	1 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
CytomX Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Puma Biotechnology beats CytomX Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Puma Biotechnology compare to Entrada Therapeutics?

Entrada Therapeutics (NASDAQ:TRDA) and Puma Biotechnology (NASDAQ:PBYI) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, earnings, media sentiment and analyst recommendations.

In the previous week, Puma Biotechnology had 5 more articles in the media than Entrada Therapeutics. MarketBeat recorded 6 mentions for Puma Biotechnology and 1 mentions for Entrada Therapeutics. Entrada Therapeutics' average media sentiment score of 1.34 beat Puma Biotechnology's score of 0.34 indicating that Entrada Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Entrada Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Puma Biotechnology	1 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Puma Biotechnology has higher revenue and earnings than Entrada Therapeutics. Entrada Therapeutics is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entrada Therapeutics	$25.42M	9.96	-$143.75M	-$3.96	N/A
Puma Biotechnology	$228.40M	2.10	$31.11M	$0.52	17.85

86.4% of Entrada Therapeutics shares are owned by institutional investors. Comparatively, 61.3% of Puma Biotechnology shares are owned by institutional investors. 9.5% of Entrada Therapeutics shares are owned by company insiders. Comparatively, 22.2% of Puma Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Puma Biotechnology has a net margin of 11.50% compared to Entrada Therapeutics' net margin of -3,537.73%. Puma Biotechnology's return on equity of 20.76% beat Entrada Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Entrada Therapeutics	-3,537.73%	-57.61%	-46.54%
Puma Biotechnology	11.50%	20.76%	13.22%

Entrada Therapeutics has a beta of -0.25, indicating that its stock price is 125% less volatile than the broader market. Comparatively, Puma Biotechnology has a beta of 1.24, indicating that its stock price is 24% more volatile than the broader market.

Entrada Therapeutics currently has a consensus price target of $17.75, suggesting a potential upside of 173.08%. Puma Biotechnology has a consensus price target of $6.00, suggesting a potential downside of 35.34%. Given Entrada Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Entrada Therapeutics is more favorable than Puma Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entrada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Puma Biotechnology	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Puma Biotechnology beats Entrada Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Puma Biotechnology compare to Mesoblast?

Puma Biotechnology (NASDAQ:PBYI) and Mesoblast (NASDAQ:MESO) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, profitability, risk, earnings, dividends and valuation.

Puma Biotechnology presently has a consensus price target of $6.00, indicating a potential downside of 35.34%. Mesoblast has a consensus price target of $39.00, indicating a potential upside of 155.07%. Given Mesoblast's higher possible upside, analysts clearly believe Mesoblast is more favorable than Puma Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Puma Biotechnology	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Mesoblast	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Puma Biotechnology has higher revenue and earnings than Mesoblast. Mesoblast is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Puma Biotechnology	$228.40M	2.10	$31.11M	$0.52	17.85
Mesoblast	$120.25M	16.51	-$57.50M	-$0.28	N/A

Puma Biotechnology has a net margin of 11.50% compared to Mesoblast's net margin of 0.00%. Puma Biotechnology's return on equity of 20.76% beat Mesoblast's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Puma Biotechnology	11.50%	20.76%	13.22%
Mesoblast	N/A	N/A	N/A

61.3% of Puma Biotechnology shares are owned by institutional investors. Comparatively, 1.4% of Mesoblast shares are owned by institutional investors. 22.2% of Puma Biotechnology shares are owned by company insiders. Comparatively, 18.8% of Mesoblast shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Puma Biotechnology had 4 more articles in the media than Mesoblast. MarketBeat recorded 6 mentions for Puma Biotechnology and 2 mentions for Mesoblast. Mesoblast's average media sentiment score of 0.83 beat Puma Biotechnology's score of 0.34 indicating that Mesoblast is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Puma Biotechnology	1 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Mesoblast	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Puma Biotechnology has a beta of 1.24, suggesting that its share price is 24% more volatile than the broader market. Comparatively, Mesoblast has a beta of 2.12, suggesting that its share price is 112% more volatile than the broader market.

Summary

Puma Biotechnology beats Mesoblast on 10 of the 15 factors compared between the two stocks.

How does Puma Biotechnology compare to Hemab Therapeutics?

Puma Biotechnology (NASDAQ:PBYI) and Hemab Therapeutics (NASDAQ:COAG) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, valuation, risk, media sentiment and analyst recommendations.

Puma Biotechnology presently has a consensus price target of $6.00, suggesting a potential downside of 35.34%. Hemab Therapeutics has a consensus price target of $51.40, suggesting a potential upside of 39.94%. Given Hemab Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Hemab Therapeutics is more favorable than Puma Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Puma Biotechnology	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Hemab Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Puma Biotechnology has higher revenue and earnings than Hemab Therapeutics. Hemab Therapeutics is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Puma Biotechnology	$228.40M	2.10	$31.11M	$0.52	17.85
Hemab Therapeutics	N/A	N/A	N/A	-$24.78	N/A

Puma Biotechnology has a net margin of 11.50% compared to Hemab Therapeutics' net margin of 0.00%. Puma Biotechnology's return on equity of 20.76% beat Hemab Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Puma Biotechnology	11.50%	20.76%	13.22%
Hemab Therapeutics	N/A	N/A	N/A

61.3% of Puma Biotechnology shares are owned by institutional investors. 22.2% of Puma Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Puma Biotechnology had 1 more articles in the media than Hemab Therapeutics. MarketBeat recorded 6 mentions for Puma Biotechnology and 5 mentions for Hemab Therapeutics. Puma Biotechnology's average media sentiment score of 0.34 beat Hemab Therapeutics' score of 0.25 indicating that Puma Biotechnology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Puma Biotechnology	1 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Hemab Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Puma Biotechnology beats Hemab Therapeutics on 10 of the 13 factors compared between the two stocks.

Get Puma Biotechnology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PBYI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PBYI vs. The Competition

Export

Metric	Puma Biotechnology	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$506.91M	$3.98B	$7.31B	$13.29B
Dividend Yield	N/A	3.63%	2.52%	12.57%
P/E Ratio	17.85	13.88	274.02	25.69
Price / Sales	2.10	1,311.42	632.76	76.07
Price / Cash	11.77	113.29	77.80	52.76
Price / Book	3.58	15.30	10.44	6.32
Net Income	$31.11M	-$22.82M	$3.49B	$359.73M
7 Day Performance	-2.52%	-1.71%	-0.66%	0.17%
1 Month Performance	1.75%	-6.17%	-3.16%	-3.27%
1 Year Performance	96.61%	30.64%	15.15%	5.58%

Puma Biotechnology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count
PBYI Puma Biotechnology	1.1933 of 5 stars	$9.28 -5.5%	$6.00 -35.3%	+97.0%	$506.91M	$228.40M	17.85	179
ADMA ADMA Biologics	3.5906 of 5 stars	$8.76 -4.2%	$18.67 +113.2%	-39.3%	$1.96B	$510.17M	12.51	647
CTMX CytomX Therapeutics	2.4409 of 5 stars	$2.84 -11.4%	$11.90 +319.8%	+31.8%	$619.93M	$76.20M	N/A	69
TRDA Entrada Therapeutics	2.2547 of 5 stars	$6.91 -2.1%	$17.75 +157.1%	+27.7%	$268.86M	$4.69M	N/A	152
MESO Mesoblast	2.0685 of 5 stars	$14.69 -2.2%	$39.00 +165.5%	-6.3%	$1.91B	$120.25M	N/A	108

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PBYI) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Puma Biotechnology (PBYI) Competitors

PBYI vs. ADMA, CTMX, TRDA, MESO, and COAG

How does Puma Biotechnology compare to ADMA Biologics?

Summary

How does Puma Biotechnology compare to CytomX Therapeutics?

Summary

How does Puma Biotechnology compare to Entrada Therapeutics?

Summary

How does Puma Biotechnology compare to Mesoblast?

Summary

How does Puma Biotechnology compare to Hemab Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PBYI vs. The Competition

Puma Biotechnology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Puma Biotechnology (PBYI) Competitors

PBYI vs. ADMA, CTMX, TRDA, MESO, and COAG

How does Puma Biotechnology compare to ADMA Biologics?

Do institutionals and insiders have more ownership in ADMA or PBYI?

Which has stronger earnings and valuation, ADMA or PBYI?

Is ADMA or PBYI more profitable?

Do analysts recommend ADMA or PBYI?

Which has more risk and volatility, ADMA or PBYI?

Does the media favor ADMA or PBYI?

Summary

How does Puma Biotechnology compare to CytomX Therapeutics?

Do insiders & institutionals believe in PBYI or CTMX?

Do analysts rate PBYI or CTMX?

Is PBYI or CTMX more profitable?

Which has higher earnings & valuation, PBYI or CTMX?

Which has more risk and volatility, PBYI or CTMX?

Does the media refer more to PBYI or CTMX?

Summary

How does Puma Biotechnology compare to Entrada Therapeutics?

Does the media refer more to TRDA or PBYI?

Which has higher valuation and earnings, TRDA or PBYI?

Do institutionals and insiders hold more shares of TRDA or PBYI?

Is TRDA or PBYI more profitable?

Which has more risk and volatility, TRDA or PBYI?

Do analysts prefer TRDA or PBYI?

Summary

How does Puma Biotechnology compare to Mesoblast?

Do analysts prefer PBYI or MESO?

Which has better valuation & earnings, PBYI or MESO?

Is PBYI or MESO more profitable?

Do insiders and institutionals believe in PBYI or MESO?

Does the media prefer PBYI or MESO?

Which has more volatility and risk, PBYI or MESO?

Summary

How does Puma Biotechnology compare to Hemab Therapeutics?

Do analysts prefer PBYI or COAG?

Which has better valuation & earnings, PBYI or COAG?

Is PBYI or COAG more profitable?

Do insiders & institutionals hold more shares of PBYI or COAG?

Does the media prefer PBYI or COAG?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PBYI vs. The Competition

Puma Biotechnology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools